Companies / BOC Sciences / Basmisanil
BOC Sciences

Basmisanil | BOC Sciences

Basmisanil is a highly selective inverse agonist/negative allosteric modulator GABAA_5 receptors. It was developed by Roche to treat cognitive impairment associated with Down syndrome. In Apr 2016, Roche completed the phase II in Down syndrome (In adolescents, In adults) in USA, Argentina, Canada, France, Italy, Mexico, New Zealand, Singapore, Spain and the UK. In Sep 2016, Phase-II clinical trials in Neurological disorders (In adults, In the elderly) in Spain was on going.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.